In this study, we exploited an inducible immunotherapeutic option to enhance CD38 expression of AML cells using ATRA for the application of T cells with anti-CD38-CAR in vitro, and suggest their useful combination in a new therapeutic strategy for AML. The gene discussed is CD38; the disease is acute myeloid leukemia.